Key catalysts targeted for 2019/2020
Boehringer Ingelheim acquired AOC3 inhibitor to report clinical proof of concept
Phase 2a NASH study in 114 patients for 3 months -last patient last visit complete.Phase 2a clinical trial result and commercial assessment to progress to Phase 2b due from BI -Q4 2019
Phase 2a diabetic retinopathy study in 100 patients for 3 months ->50% recruited Clinical and commercial assessment due from BI -mid 2020
LOXL2 anti fibrotic program
Partnering process to conclude -H2 2019
Mannitol Business (Aridol & Bronchitol) to turn profitable in 2020
US -FDA to complete review H1 2020; if approved -launch milestone US$10m
Sales growth in existing and new territories expected to continue
do not advertise external links.au/upload/CKEditor/untitled%20folder%201/triple2.jpg
- Forums
- ASX - By Stock
- PXS=MC $75 M --2 Marketed Products --MEGA Milestones IMMINENT =Disallowed or Buyout Gem
Key catalysts targeted for 2019/2020Boehringer Ingelheim...
-
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SNT (ASX) to my watchlist
|
|||||
Last
3.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $41.29M |
Open | High | Low | Value | Volume |
3.2¢ | 3.2¢ | 3.2¢ | $30.50K | 953.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 1747120 | 3.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.3¢ | 850000 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 1747120 | 0.031 |
3 | 1146000 | 0.030 |
5 | 1553052 | 0.029 |
6 | 2415714 | 0.028 |
1 | 1000000 | 0.027 |
Price($) | Vol. | No. |
---|---|---|
0.033 | 850000 | 3 |
0.034 | 1000000 | 1 |
0.035 | 36518 | 2 |
0.036 | 243902 | 1 |
0.037 | 134500 | 1 |
Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
Featured News
SNT (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online